)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
IN8bio
IN8bio (INAB) investor relations material
IN8bio Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary12 Mar, 2026
Executive summary
Achieved significant clinical progress in glioblastoma, with repeat dosing of DeltEx Drug-Resistant Immunotherapy T cells nearly doubling median progression-free survival to 13.0 months versus 6.6 months for standard-of-care controls (+97%).
Advanced gamma-delta T cell therapies and T cell engager pipeline, with multiple milestones expected in 2026.
Strengthened financial position through a $20.1 million private placement, extending cash runway into the first half of 2027.
Financial highlights
Cash position at December 31, 2025 was $27.1 million, more than double the prior year’s $11.1 million.
Full-year net loss reduced by 36% year-over-year to $19.4 million, or $4.44 per share, compared to $30.4 million, or $17.05 per share, in 2024.
R&D expenses for 2025 were $10.2 million, down from $17.0 million in 2024; G&A expenses were $9.7 million, down from $12.6 million.
No severance or related charges in 2025, compared to $1.1 million in 2024.
Outlook and guidance
FDA guidance on regulatory pathway for GBM program expected in the second half of 2026.
Additional clinical updates, including final median overall survival data, anticipated at medical meetings in mid- and late-2026.
Initial preclinical animal data for INB-619 expected in the second half of 2026.
Completion of patient dosing in INB-100 and long-term follow-up results expected in 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from IN8bio
- Repeat gamma delta T cell dosing in glioblastoma yields superior survival and safety outcomes.INAB
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Gamma-delta T cell therapies show durable remissions and major survival gains in glioblastoma.INABNoble Capital Markets’ Emerging Growth Virtual Equity Conference5 Feb 2026
- Durable remissions and broad immune targeting drive optimism for upcoming gamma delta T cell data.INABH.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference3 Feb 2026
- INB-100 prioritized for leukemia after strong early results; other programs paused amid funding challenges.INABH.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026
- 14.4M shares registered for resale from a private placement; no proceeds to the company.INABRegistration Filing20 Jan 2026
- Durable remissions and extended survival achieved with gamma delta T cell therapies in cancer.INABBiotech Showcase 202510 Jan 2026
- Gamma-delta T cell platform shows durable remissions and safer B cell depletion in trials.INABTD Cowen 45th Annual Healthcare Conference26 Dec 2025
- Gamma delta T-cell therapies achieve durable remissions and high survival in complex cancers.INABH.C. Wainwright 3rd Annual Cell Therapy Virtual Conference26 Dec 2025
- INB-100 achieved 100% one-year remission and survival in high-risk AML with minimal side effects.INABStudy Result19 Dec 2025
IN8bio
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
IN8bio Inc., previously known as Incysus Therapeutics, is a clinical-stage biopharmaceutical company focused on the development of innovative gamma-delta T cell therapies for cancer treatment. Their portfolio includes lead product candidates in various phases of clinical trials, targeting conditions such as glioblastoma and acute leukemia, alongside a broad spectrum of preclinical programs aimed at solid tumors. Utilizing their proprietary DeltEx platform, IN8bio develops both autologous and allogeneic gamma-delta T cell therapies, leveraging the unique properties of gamma-delta T cells to differentiate between healthy and diseased tissues. The company was established in 2016 and is headquartered in New York, New York, with its primary scientific operations based in Birmingham, Alabama. Its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage